Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia. The aim of this is to investigate the efficacy and safety of
activated recombinant human factor VII (rFVIIa) in achieving haemostasis in patients with
Dengue haemorrhagic fever (DHF).